Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv [Archive]

View Full Version : Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv

News

10-31-2009, 04:11 AM

Eisai Inc. announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

More... (http://www.medicalnewstoday.com/articles/169384.php)